{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:02:52Z","timestamp":1770814972545,"version":"3.50.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Coronary disorders are recognized as the most common manifestation of fluoropyrimidine-related cardiotoxicity in clinical practice. However, there are limited and conflicting data on the incidence and profiles of fluoropyrimidine-related coronary disorders. In this meta-analysis, we aimed to systematically assess the incidence of all-grade and grade 3 or higher fluoropyrimidine-related coronary disorders, and further explore the factors that influence its occurrence.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Studies reporting the fluoropyrimidine-related coronary disorders were retrieved from a systematic search of English literature in the PubMed, Web of Science, Medline, and Cochrane database from 1 Jan 2001, to 1 Jan 2022. The NIH assessment tool was used to evaluate the quality of each study. The data of basic study characteristics, treatment details, and results of coronary toxicities were extracted. According to the results of the heterogeneity test (I<jats:sup>2<\/jats:sup> and <jats:italic>p<\/jats:italic>-value statistic), a random-effect model or fixed-effect model was selected for the pooled analysis of the incidence of adverse coronary events. Subgroup analysis was conducted to further explore the risks influencing the occurrence of fluoropyrimidine-related coronary disorders. The stability and publication bias of our results were evaluated by sensitivity analysis and Egger test, respectively.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 63 studies were finally included in our pooled analysis, involving 25,577 patients. The pooled cumulative incidence of all-grade and grade 3 or higher coronary disorders was 2.75% (95% CI 1.89%\u20133.76%) and 1.00% (95% CI 0.62%\u20131.47%), respectively. The coronary disorders were most reported as myocardial ischemia (1.28%, 95% CI 0.42%\u20132.49%) and angina\/chest pain (1.1%, 95% CI 0.54%\u20131.81%). Subgroup analysis revealed that studies in the female-only population seemed to have a lower incidence of fluoropyrimidine-related coronary disorders. The occurrence of adverse coronary events varied among different tumor types. Patients with esophageal cancer have the highest coronary toxicity (6.32%), while those with breast cancer have a relatively lower incidence (0.5%). Coronary disorders induced by 5-FU monotherapy are more frequent than that induced by capecitabine (3.31% vs. 1.21%, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). Fluoropyrimidine combination therapy, whether combined with other chemotherapy drugs, targeted therapy drugs, or radiotherapy, significantly increased the incidence of coronary complications (<jats:italic>p<\/jats:italic> &amp;lt; 0.01).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This meta-analysis has defined the incidence of fluoropyrimidine-related coronary disorders and depicted its epidemiological profiles for the first time, which may provide a reference for clinical practice in cancer management.<\/jats:p>","DOI":"10.3389\/fphar.2022.885699","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T09:15:28Z","timestamp":1652433328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yajie","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizhou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongyi","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongchen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clcc.2018.10.006","article-title":"5-Fluorouracil-related Cardiotoxicity; Findings from Five Randomized Studies of 5-Fluorouracil-Based Regimens in Metastatic Colorectal Cancer","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1200\/jco.2008.26.15_suppl.15085","article-title":"Bevacizumab Added to the Irinotecan and Capecitabine Combination for Advanced Colorectal Cancer: A Well-Tolerated, Active and Convenient Regimen","volume":"28","author":"Ardavanis","year":"2008","journal-title":"Anticancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.drugalcdep.2015.07.446","article-title":"A Phase II Trial of Docetaxel, Cisplatin and 5-fluorouracil in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)","volume":"26","author":"Baghi","year":"2006","journal-title":"Anticancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/S0735-1097(18)32865-1","article-title":"A Case of 5-Fluorouracil-Induced Coronary Artery Vasovasospasm in Rectal Adenocarcinoma","author":"Baldeo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/ol_00000035","article-title":"Chemoradiotherapy with 5-fluorouracil\/leucovorin, Surgery and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer","volume":"1","author":"Baur","year":"2010","journal-title":"Oncol. Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small Molecules, Big Impact: 20 Years of Targeted Therapy in Oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.ajem.2017.02.046","article-title":"Prinzmetal Angina (Coronary Vasospasm) Associated with 5-fluorouracil Chemotherapy","volume":"35","author":"Ben-Yakov","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1634\/theoncologist.2019-0437","article-title":"Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)","volume":"25","author":"Chakravarthy","year":"2020","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1097\/COC.0000000000000465","article-title":"A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer","volume":"41","author":"Chen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","article-title":"Neoadjuvant Capecitabine and Oxaliplatin before Chemoradiotherapy and Total Mesorectal Excision in MRI-Defined Poor-Risk Rectal Cancer: a Phase 2 Trial","volume":"11","author":"Chua","year":"2010","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"644279","DOI":"10.3389\/fcvm.2021.644279","article-title":"The Link between Sex Hormones and Susceptibility to Cardiac Arrhythmias: From Molecular Basis to Clinical Implications","volume":"8","author":"Costa","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5694\/mja2.50317","article-title":"5-Fluorouracil-induced Acute Coronary Syndrome","volume":"211","author":"Das","year":"2019","journal-title":"Med. J. Aust."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.5306\/wjco.v11.i12.1008","article-title":"Fluoropyrimidine-induced Cardiotoxicity","volume":"11","author":"Deac","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1200\/JCO.19.01371","article-title":"Standard Anthracycline Based versus Docetaxel-Capecitabine in Early High Clinical And\/or Genomic Risk Breast Cancer in the EORTC 10041\/BIG 3-04 MINDACT Phase III Trial","volume":"38","author":"Delaloge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000055129","article-title":"Adjuvant Radio-Chemotherapy in Stage II-III Rectal Cancer with 24-hour Infusion of High-Dose 5-fluorouracil and Folinic Acid: Evaluation of Feasibility","volume":"24","author":"Dencausse","year":"2001","journal-title":"Onkologie"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced Cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"E403","DOI":"10.1002\/onco.13536","article-title":"Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study","volume":"26","author":"Dyhl-Polk","year":"","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","article-title":"Incidence and Risk Markers of 5-fluorouracil and Capecitabine Cardiotoxicity in Patients with Colorectal Cancer","volume":"59","author":"Dyhl-Polk","year":"","journal-title":"Acta Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer Therapy and Cardiovascular Risk: Focus on Bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2407-7-91","article-title":"Front-line Bevacizumab in Combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in Patients with Metastatic Colorectal Cancer: a Multicenter Phase II Study","volume":"7","author":"Emmanouilides","year":"2007","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1200\/JCO.2005.06.035","article-title":"Capecitabine as First-Line Treatment for Patients Older Than 70 Years with Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study","volume":"23","author":"Feliu","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/S0735-1097(19)33083-9","article-title":"5-fluorouracil Induced Coronary Vasospasm and Non-ischemic Cardiomyopathy Presenting in the Same Patient","volume":"73","author":"Gao","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl005","article-title":"Docetaxel and Capecitabine in Patients with Metastatic Adenocarcinoma of the Stomach and Gastroesophageal junction: a Phase II Study from the North Central Cancer Treatment Group","volume":"17","author":"Giordano","year":"2006","journal-title":"Ann. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CRD.0b013e318259294b","article-title":"Effect of Female Sex on Cardiac Arrhythmias","volume":"20","author":"Gowd","year":"2012","journal-title":"Cardiol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/jgo.2019.11.06","article-title":"Phase Ib\/II Study Combining Tosedostat with Capecitabine in Patients with Advanced Pancreatic Adenocarcinoma","volume":"11","author":"Grierson","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000055126","article-title":"Phase II Study of a Weekly 24-hour Infusion with 5-fluorouracil and Simultaneous Sodium-Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer","volume":"24","author":"Hartung","year":"2001","journal-title":"ONKOLOGIE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12885-019-5421-y","article-title":"The Heart's Exposure to Radiation Increases the Risk of Cardiac Toxicity after Chemoradiotherapy for Superficial Esophageal Cancer: a Retrospective Cohort Study","volume":"19","author":"Hayashi","year":"2019","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of Oral Capecitabine versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Study","volume":"19","author":"Hoff","year":"20012001","journal-title":"Jco"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdj063","article-title":"Oxaliplatin and Capecitabine in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal junction and Gastric Cardia: a Phase II Study from the North Central Cancer Treatment Group","volume":"17","author":"Jatoi","year":"2006","journal-title":"Ann. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil Induces Myocardial Ischemia with Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but without Dysfunction of Left Ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk Factors and Prevention of Cardiotoxicity Induced by 5-fluorouracil or Capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00280-019-03888-1","article-title":"Incidence of and Risk Factors for Cardiotoxicity after Fluorouracil-Based Chemotherapy in Locally Advanced or Metastatic Gastric Cancer Patients","volume":"84","author":"Jin","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, Epirubicin, and Cyclophosphamide with Either Docetaxel or Vinorelbine, with or without Trastuzumab, as Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-Associated Cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol. Clin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5543\/tkda.2015.36005","article-title":"Capecitabine-induced Coronary Artery Vasospasm in a Patient Who Previously Experienced a Similar Episode with Fluorouracil Therapy","volume":"44","author":"Karakulak","year":"2016","journal-title":"Turk Kardiyol Dern Ars"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S1470-2045(16)30172-3","article-title":"Adjuvant Capecitabine Plus Bevacizumab versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): an Open-Label, Randomised Phase 3 Trial","volume":"17","author":"Kerr","year":"2016","journal-title":"Lancet Oncol."},{"key":"B43","first-page":"430","article-title":"A Retrospective Study of Cardiotoxicities Induced by 5-fluouracil (5-FU) and 5-FU Based Chemotherapy Regimens in Pakistani Adult Cancer Patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J. Pak Med. Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and Electrocardiography Changes in Patients Treated with Capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdl179","article-title":"Randomised Study of Sequential versus Combination Chemotherapy with Capecitabine, Irinotecan and Oxaliplatin in Advanced Colorectal Cancer, an Interim Safety Analysis. A Dutch Colorectal Cancer Group (DCCG) Phase III Study","volume":"17","author":"Koopman","year":"2006","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of Fluoropyrimidines in Different Schedules of Administration: a Prospective Study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","article-title":"Cardio-oncology: A Focus on Cardiotoxicity","volume":"13","author":"Koutsoukis","year":"2018","journal-title":"Eur. Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1254\/jphs.08r23fm","article-title":"New Aspects for the Treatment of Cardiac Diseases Based on the Diversity of Functional Controls on Cardiac Muscles: Acute Effects of Female Hormones on Cardiac Ion Channels and Cardiac Repolarization","volume":"109","author":"Kurokawa","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of Capecitabine-Related Cardiotoxicity in Different Treatment Schedules of Metastatic Colorectal Cancer: A Retrospective Analysis of the CAIRO Studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40268-016-0154-8","article-title":"Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study","volume":"17","author":"Leicher","year":"2017","journal-title":"Drugs R. D"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1254","DOI":"10.1634\/theoncologist.2020-0053","article-title":"Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare as it Seems","volume":"25","author":"Lestuzzi","year":"2020","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort Myocardial Ischemia during Chemotherapy with 5-fluorouracil: an Underestimated Risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"103346","DOI":"10.1016\/j.critrevonc.2021.103346","article-title":"Risk Factors of Fluoropyrimidine Induced Cardiotoxicity Among Cancer Patients: A Systematic Review and Meta-Analysis","volume":"162","author":"Li","year":"2021","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/sj.bjc.6602697","article-title":"Phase II Study of Weekly Oxaliplatin Plus Infusional Fluorouracil and Folinic Acid (FUFOX Regimen) as First-Line Treatment in Metastatic Gastric Cancer","volume":"93","author":"Lordick","year":"2005","journal-title":"Br. J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/JCN.0000000000000380","article-title":"The Value of Detecting Asymptomatic Signs of Myocardial Ischemia in Patients with Coronary Artery Disease in Outpatient Cardiac Rehabilitation","volume":"32","author":"Lounsbury","year":"2017","journal-title":"J. Cardiovasc. Nurs."},{"key":"B57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/annonc\/mdl460","article-title":"Phase I\/II Study of Preoperative Cetuximab, Capecitabine, and External Beam Radiotherapy in Patients with Rectal Cancer","volume":"18","author":"Machiels","year":"2007","journal-title":"Ann. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/978-3-642-04346-8_23","article-title":"Intra-arterial Infusion of 5-fluorouracil, Leucovorin, Epirubicin and Carboplatin (FLEC Regimen) in Unresectable Pancreatic Cancer: Results of a Ten-Year Experience","volume":"20","author":"Mambrini","year":"2006","journal-title":"In Vivo"},{"key":"B59","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1634\/theoncologist.2011-0344","article-title":"Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-Positive Locally Recurrent or Metastatic Breast Cancer","volume":"17","author":"Mart\u00edn","year":"2012","journal-title":"Oncologist"},{"key":"B60","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (Irinotecan, Oxaliplatin, Fluorouracil, and Folinate) as First-Line Treatment for Metastatic Colorectal Cancer: a Phase 2 Trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/nejmoa1414325","article-title":"Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jjco\/hyi071","article-title":"Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-up","volume":"35","author":"Meydan","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/jco.2009.27.15_suppl.1111","article-title":"Trastuzumab Plus Capecitabine and Docetaxel as First-Line Therapy for HER2-Positive Metastatic Breast Cancer: Phase II Results","volume":"30","author":"Michalaki","year":"2010","journal-title":"Anticancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/eurheartj\/ehy563.P4788","article-title":"P47885-Fluorouracil Cardiotoxicity: the Role of Oxidative Stress, Apoptosis, Inflammation and Endothelial Dysfuction","volume":"39","author":"Mohammed","year":"2018","journal-title":"Eur. Heart J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11886-021-01441-2","article-title":"5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death","volume":"23","author":"More","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The Frequency and Pattern of Cardiotoxicity Observed with Capecitabine Used in Conjunction with Oxaliplatin in Patients Treated for Advanced Colorectal Cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"B68","volume-title":"National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)","year":"2020"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","article-title":"Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points from National Surgical Adjuvant Breast and Bowel Project Trial R-04","volume":"32","author":"O'Connell","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/annonc\/mds533","article-title":"Bevacizumab with Peri-Operative Epirubicin, Cisplatin and Capecitabine (ECX) in Localised Gastro-Oesophageal Adenocarcinoma: a Safety Report","volume":"24","author":"Okines","year":"2013","journal-title":"Ann. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf."},{"key":"B72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/A:1011107105538","article-title":"High-dose Radiation Therapy and Neoadjuvant Plus Concomitant Chemotherapy with 5-fluorouracil and Cisplatin in Patients with Locally Advanced Squamous-Cell Anal Canal Cancer: Final Results of a Phase II Study","volume":"12","author":"Peiffert","year":"2001","journal-title":"Ann. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-018-0292-1","article-title":"Cardiotoxicity of 5-fluorouracil and Capecitabine in Chinese Patients: a Prospective Study","volume":"38","author":"Peng","year":"2018","journal-title":"Cancer Commun. (Lond)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","article-title":"Phase II Trial of Sorafenib in Combination with 5-fluorouracil Infusion in Advanced Hepatocellular Carcinoma","volume":"69","author":"Petrini","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e012798","DOI":"10.1136\/bmjopen-2016-012798","article-title":"Incidence and Risk Factors for Capecitabine-Induced Symptomatic Cardiotoxicity: a Retrospective Study of 452 Consecutive Patients with Metastatic Breast Cancer","volume":"6","author":"Polk","year":"2016","journal-title":"BMJ Open"},{"key":"B76","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): a Randomised, Controlled, Multicentre, Phase 3 Study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"E606","DOI":"10.1634\/theoncologist.2019-0762","article-title":"Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study","volume":"25","author":"Raber","year":"2019","journal-title":"Oncologist"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and Cardiotoxicity: a Review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/1078155218774871","article-title":"Capecitabine-induced Myopericarditis - A Case Report and Review of Literature","volume":"25","author":"Saunders","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(21)03914-0","article-title":"A Rare Case of Acute Coronary Syndrome Induced by Oral Capecitabine","volume":"195","author":"Sedhom","year":"2017","journal-title":"Am. J. Resp. Crit. Care"},{"key":"B81","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2407-9-120","article-title":"Capecitabine Plus Irinotecan (XELIRI Regimen) Compared to 5-FU\/LV Plus Irinotecan (FOLFIRI Regimen) as Neoadjuvant Treatment for Patients with Unresectable Liver-Only Metastases of Metastatic Colorectal Cancer: a Randomised Prospective Phase II Trial","volume":"9","author":"Skof","year":"2009","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of Anthracycline Agents for the Treatment of Cancer: Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00432-013-1409-1","article-title":"Efficacy and Toxicity of Trastuzumab and Paclitaxel Plus Capecitabine in the First-Line Treatment of HER2-Positive Metastatic Breast Cancer","volume":"139","author":"Tonyali","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"PI51","DOI":"10.12659\/MSM.936523","article-title":"Cardiotoxicity Following Different Doses and Schedules of 5-fluorouracil Administration for Malignancy -- a Survey of 427 Patients","volume":"8","author":"Tsavaris","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"B85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0003319716637516","article-title":"Usefulness of Heart-type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity","volume":"68","author":"Turan","year":"2017","journal-title":"Angiology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0360-3016(02)02772-4","article-title":"A Single-Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies","volume":"53","author":"Vaishampayan","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of Cardiotoxicity with the Oral Fluoropyrimidine Capecitabine Is Typical of that Reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann. Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000072334","article-title":"High Incidence of Angina Pectoris in Patients Treated with 5-fluorouracil. A Planned Surveillance Study with 102 Patients","volume":"65","author":"Wacker","year":"2003","journal-title":"ONCOLOGY"},{"key":"B89","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3109\/0284186X.2016.1161825","article-title":"Experience with S-1 in Older Caucasian Patients with Metastatic Colorectal Cancer (mCRC): Findings from an Observational Chart Review","volume":"55","author":"Winther","year":"2016","journal-title":"Acta Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00280-007-0497-5","article-title":"A Phase II Study of Trastuzumab and Capecitabine for Patients with HER2-Overexpressing Metastatic Breast Cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jso.20503","article-title":"Preoperative Chemoradiation in Rectal Cancer: Retrospective Comparison between Capecitabine and Continuous Infusion of 5-fluorouracil","volume":"93","author":"Yerushalmi","year":"2006","journal-title":"J. Surg. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","article-title":"5-Fluorouracil Increases the Number and Complexity of Premature Complexes in the Heart: a Prospective Study Using Ambulatory ECG Monitoring","volume":"61","author":"Yilmaz","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"B93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The Incidence, Risk Factors, and Outcomes with 5-Fluorouracil-Associated Coronary Vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(17)30088-8","article-title":"Utidelone Plus Capecitabine versus Capecitabine Alone for Heavily Pretreated Metastatic Breast Cancer Refractory to Anthracyclines and Taxanes: a Multicentre, Open-Label, Superiority, Phase 3, Randomised Controlled Trial","volume":"18","author":"Zhang","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.885699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T09:15:32Z","timestamp":1652433332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.885699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":93,"alternative-id":["10.3389\/fphar.2022.885699"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.885699","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"article-number":"885699"}}